SOURCE: Xtalks

Xtalks Webinars

January 26, 2015 07:05 ET

Multiparametric Flow Cytometry Analysis of Cell-Mediated Immunity in Clinical Trials: A Case-Study Using Plant-Derived Virus-Like Particles (VLP) in Influenza Vaccines, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - January 26, 2015) - In this scientific webinar, industry experts Jean-Francois Poulin, Senior Principal Scientist and Business Development Liaison at Caprion/IMMUNECARTA Services, and Stéphane Pillet, Immunology Scientist at Medicago Inc., will describe how the production of Virus-Like Particle (VLP)-based vaccines using plant-based transient expression technology has particular advantages for accelerating both the development of new vaccines and the scaling-up of production for deployment in affected areas.

Vaccine lots, which exactly match the specific strain(s) in circulation can be generated within a month of strain identification. This is a significant improvement compared to more traditional fertilized chicken egg-based platforms, which require half a year or more for viral strain production. Plant-based VLP technology is rapid, scalable and relatively low-cost, with the added safety advantage that the VLP contains no genetic material, rendering it non-infectious and unable to replicate.

Hemagglutination inhibition (HI) antibody titers, the only universally accepted immune correlate of protection against influenza, does not necessarily translate into protection, and clinical benefit may be short-lived, particularly in the elderly. Recent studies in animal models have suggested that in situations where antibodies fail to confer protection, cell-mediated immunity may be able to act alone, suggesting that some shortcomings currently associated with influenza vaccines might be surmounted via use of novel vaccines which elicit CD4 and CD8 T cell responses. Therefore, in the current clinical immune monitoring study, the specificity and magnitude of CD4 and CD8 T cell response were measured following immunization.

Along with a case study, the speakers will also present data to show how multiparametric flow cytometry and related analytical tools allow monitoring the diversity and distribution of Influenza-specific cellular subsets both at the phenotypic and functional level in the context of a clinical trial.

Join the live broadcast on Tuesday, February 17, 2015 at 11am EST (4pm GMT). The 60-minute presentation will include a Q&A session with the audience. To learn more about this event visit: Multiparametric Flow Cytometry Analysis of Cell-mediated Immunity in Clinical Trials

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2015/1/23/11G031219/Images/logo_big_caprion-1045142329352.jpg

Contact Information